Immunotherapy and vaccination after transplant: the present, the future.
Vaccination and adoptive immunotherapy for herpes virus infections has become an attractive option for the control of a virus family that negatively affects transplantation. In the future, enhanced ability to select antigen-specific T cells without significant in vitro manipulation should provide new opportunities for refining and enhancing adoptive immunotherapeutic approaches. This article focuses on advances in the area of vaccinology for some of these infections and in the use of adoptive immunotherapy. At present, many of these approaches in transplant recipients have focused on infections such as human cytomegalovirus, but the opportunity to use these examples as proof of concept for other infections is discussed.
Emery
Vincent C
VC
Department of Infection, University College London, Rowland Hill Street, Hampstead, London NW3 2QG, UK. v.emery@ucl.ac.uk
Einsele
Hermann
H
Atabani
Sowsan
S
Haque
Tanzina
T
D003141:Communicable Diseases / Q000188:drug therapy*; D006801:Humans; D016867:Immunocompromised Host; D007167:Immunotherapy / Q000379:methods* / Q000639:trends*; D014180:Transplantation / Q000009:adverse effects*; D014611:Vaccination / Q000379:methods* / Q000639:trends*